1. Scrip
  2. >>Drug Pricing

Arteryex Acquisition To Enhance Eisai's Digital Strategy

Tokyo Venture Adds To Digital Service Platform

 
• By Lisa Takagi

Eisai is acquiring Japanese software company Arteryex as part of a digital shift strategy, with the two companies to work together to develop and provide services around personal data, including health records.

Eisai acquires Arteryex, a Japanese IT company
Eisai and Arteryex will work together to develop digital services • Source: Alamy

Eisai Co., Ltd. announced the acquisition of Japanese software company Arteryex on 1 April 2022, in a move in line with its recent strategy to shift to digital healthcare services.

The major Japanese pharma firm intends to co-develop and provide with the private Tokyo-based venture personal services through mobile applications...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

UroGen Gets A First-Ever Bladder Cancer Approval Despite US FDA AdComm ‘No’ Vote

 
• By Joseph Haas

UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.

Europe’s Drugmakers Lament EU Pharma Package

 
• By Kevin Grogan

EFPIA says reforms make the continent less attractive for innovative firms.

Stock Watch: Q1 Sales Trends And Forex Muddle Pharma Outlook

 
• By Andy Smith

Pharma firms tended to downplay first-quarter trends in full-year guidance. However, raised guidance seems fragile amid ongoing foreign exchange effects and Medicare Part D redesign pressures.

HHS Intensifies Pressure On Pharma With MFN Pricing Benchmark

 
• By Jessica Merrill

The Trump administration released more details on “most favored nation” price targets drug companies are expected to apply to US drug prices.

More from Scrip